Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab.
Ellis
Lee M
LM
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Curley
Steven A
SA
Grothey
Axel
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000473:pathology*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D008115:Liver Regeneration; D020360:Neoadjuvant Therapy; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab